256 related articles for article (PubMed ID: 17208339)
21. Effectiveness of the 7-valent pneumococcal conjugate vaccine in children with sickle cell disease in the first decade of life.
Adamkiewicz TV; Silk BJ; Howgate J; Baughman W; Strayhorn G; Sullivan K; Farley MM
Pediatrics; 2008 Mar; 121(3):562-9. PubMed ID: 18310206
[TBL] [Abstract][Full Text] [Related]
22. Cost-effectiveness of pneumococcal conjugate vaccine: evidence from the first 5 years of use in the United States incorporating herd effects.
Ray GT; Whitney CG; Fireman BH; Ciuryla V; Black SB
Pediatr Infect Dis J; 2006 Jun; 25(6):494-501. PubMed ID: 16732146
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of pneumococcal conjugate vaccination in Georgia.
Komakhidze T; Hoestlandt C; Dolakidze T; Shakhnazarova M; Chlikadze R; Kopaleishvili N; Goginashvili K; Kherkheulidze M; Clark AD; Blau J
Vaccine; 2015 May; 33 Suppl 1():A219-26. PubMed ID: 25919165
[TBL] [Abstract][Full Text] [Related]
24. Childhood invasive pneumococcal disease in Germany between 1997 and 2003: variability in incidence and serotype distribution in absence of general pneumococcal conjugate vaccination.
Rückinger S; von Kries R; Reinert RR; van der Linden M; Siedler A
Vaccine; 2008 Jul; 26(32):3984-6. PubMed ID: 18495301
[TBL] [Abstract][Full Text] [Related]
25. Economic evaluation of a universal childhood pneumococcal conjugate vaccination strategy in Ireland.
Tilson L; Usher C; Butler K; Fitzsimons J; O'Hare F; Cotter S; O'Flanagan D; Johnson H; Barry M
Value Health; 2008; 11(5):898-903. PubMed ID: 18489504
[TBL] [Abstract][Full Text] [Related]
26. Economic evaluation of pneumococcal conjugate vaccination in The Gambia.
Kim SY; Lee G; Goldie SJ
BMC Infect Dis; 2010 Sep; 10():260. PubMed ID: 20815900
[TBL] [Abstract][Full Text] [Related]
27. Pharmacoeconomics of elderly vaccination against invasive pneumococcal infections: cost-effectiveness analyses and implications for The Netherlands.
Postma MJ; Heijnen ML; Beutels P; Jager JC
Expert Rev Vaccines; 2003 Aug; 2(4):477-82. PubMed ID: 14711333
[TBL] [Abstract][Full Text] [Related]
28. Cost effectiveness analysis of heptavalent pneumococcal conjugate vaccine in Germany considering herd immunity effects.
Claes C; Reinert RR; von der Schulenburg JM
Eur J Health Econ; 2009 Feb; 10(1):25-38. PubMed ID: 18379830
[TBL] [Abstract][Full Text] [Related]
29. Management of antibiotic-resistant Streptococcus pneumoniae infections and the use of pneumococcal conjugate vaccines.
Picazo JJ
Clin Microbiol Infect; 2009 Apr; 15 Suppl 3():4-6. PubMed ID: 19366362
[TBL] [Abstract][Full Text] [Related]
30. Effectiveness of a 2+1 dose schedule pneumococcal conjugate vaccination programme on invasive pneumococcal disease among children in Norway.
Vestrheim DF; Løvoll O; Aaberge IS; Caugant DA; Høiby EA; Bakke H; Bergsaker MR
Vaccine; 2008 Jun; 26(26):3277-81. PubMed ID: 18456376
[TBL] [Abstract][Full Text] [Related]
31. The potential cost-effectiveness of infant pneumococcal vaccines in Australia.
Newall AT; Creighton P; Philp DJ; Wood JG; MacIntyre CR
Vaccine; 2011 Oct; 29(45):8077-85. PubMed ID: 21864617
[TBL] [Abstract][Full Text] [Related]
32. [Economic evaluation of an infant immunization program in Mexico, based on 13-valent pneumococcal conjugated vaccines].
Muciño-Ortega E; Mould-Quevedo JF; Farkouh R; Strutton D
Value Health; 2011; 14(5 Suppl 1):S65-70. PubMed ID: 21839902
[TBL] [Abstract][Full Text] [Related]
33. Cost effectiveness of pneumococcal conjugate vaccination against acute otitis media in children: a review.
Boonacker CW; Broos PH; Sanders EA; Schilder AG; Rovers MM
Pharmacoeconomics; 2011 Mar; 29(3):199-211. PubMed ID: 21250759
[TBL] [Abstract][Full Text] [Related]
34. New vaccines against otitis media: projected benefits and cost-effectiveness.
O'Brien MA; Prosser LA; Paradise JL; Ray GT; Kulldorff M; Kurs-Lasky M; Hinrichsen VL; Mehta J; Colborn DK; Lieu TA
Pediatrics; 2009 Jun; 123(6):1452-63. PubMed ID: 19482754
[TBL] [Abstract][Full Text] [Related]
35. Impact of pneumococcal conjugate vaccine on infections caused by antibiotic-resistant Streptococcus pneumoniae.
Dagan R
Clin Microbiol Infect; 2009 Apr; 15 Suppl 3():16-20. PubMed ID: 19366365
[TBL] [Abstract][Full Text] [Related]
36. Cost Effectiveness of Pneumococcal Vaccination in Children in Low- and Middle-Income Countries: A Systematic Review.
Saokaew S; Rayanakorn A; Wu DB; Chaiyakunapruk N
Pharmacoeconomics; 2016 Dec; 34(12):1211-1225. PubMed ID: 27510721
[TBL] [Abstract][Full Text] [Related]
37. Pneumococcal conjugate vaccine: economic issues of the introduction of a new childhood vaccine.
Ray GT
Expert Rev Vaccines; 2002 Jun; 1(1):65-74. PubMed ID: 12908513
[TBL] [Abstract][Full Text] [Related]
38. Effectiveness of abbreviated and delayed 7-valent pneumococcal conjugate vaccine dosing regimens.
Mahon BE; Hsu K; Karumuri S; Kaplan SL; Mason EO; Pelton SI; ;
Vaccine; 2006 Mar; 24(14):2514-20. PubMed ID: 16417951
[TBL] [Abstract][Full Text] [Related]
39. Cost-effectiveness of pneumococcal conjugate vaccine: an update after 7 years of use in the United States.
Ray GT; Pelton SI; Klugman KP; Strutton DR; Moore MR
Vaccine; 2009 Nov; 27(47):6483-94. PubMed ID: 19720366
[TBL] [Abstract][Full Text] [Related]
40. Immunogenicity, efficacy, safety and effectiveness of pneumococcal conjugate vaccines (1998-2006).
Oosterhuis-Kafeja F; Beutels P; Van Damme P
Vaccine; 2007 Mar; 25(12):2194-212. PubMed ID: 17267077
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
